Akash Maity

Akash Maity

Auto-generated profile, based on publicly available information

Akash Maity

Hasan Laboratory, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2025 in Blood Advances
Verified
Journal Article
Open access
AMAkash Maity
Akash Maity
ASAmritha Sathyanarayanan
Amritha Sathyanarayanan
RKRohit Kumar
Rohit Kumar
JVJesal Vora
Jesal Vora
JGJitendra Gawde
Jitendra Gawde
SHSyed Hasan
Syed Hasan
Acute promyelocytic leukemia (APL), distinguished by the presence of PML::RARA fusion transcript, is a medical emergency because of its high early death rate, which is preventable when diagnosed early. Current diagnostic methods are precise and reliable but are time intensive, require sophisticated instruments, and analytical expertise. This study has redefined APL identification by CRISPR system (RAPID-CRISPR) to rapidly (<3 hours) detect PML::RARA. APL cell lines (NB4 and UF-1) and bone marrow/peripheral blood samples from 74 patients with APL (66/8, retrospective/prospective) and 48 controls were included in the study. We used a DETECTR (DNA endonuclease-targeted CRISPR transreporter) assay to identify the bcr1, bcr2, and bcr3 PML::RARA isoforms. To ensure high specificity, we used PML::RARA–specific loop-mediated isothermal amplification (LAMP) primers, synthetic protospacer-adjacent motif sites, and isoform-specific CRISPR RNAs. RAPID-CRISPR recognized APL with 100% sensitivity and 100% specificity in an ambispective cohort of patient samples. Furthermore, our blinded validation approach to detect PML::RARA in an unbiased manner provides an additional layer in the diagnostic precision of APL. RAPID-CRISPR demonstrated superior sensitivity, detecting as few as 1 copy of PML::RARA compared with 10 copies by the gold-standard reverse transcriptase qualitative and quantitative polymerase chain reaction. The nucleic acid extraction–free protocol combined with the 1-step reverse transcriptase LAMP–based DETECTR followed by lateral flow readout makes the RAPID-CRISPR assay suitable for diagnosing APL in point-of-care settings. This simple, cost-effective tool, with its easy-to-read format, is particularly valuable in underresourced regions. The assay facilitates timely diagnosis and prompt administration of lifesaving therapies such as all-trans retinoic acid and arsenic trioxide in APL.

12 February 2026 in Molecular Carcinogenesis
Verified
Journal Article
Open access
AMAkash Maity
Akash Maity
RKRohit Kumar
Rohit Kumar
MDMadhavi Dutta
Madhavi Dutta
AMAnsit Mishra
Ansit Mishra
JGJitendra Gawde
Jitendra Gawde
SHSyed Hasan
Syed Hasan
Early diagnosis of acute promyelocytic leukemia (APL), driven by PML‐RARA oncoprotein, is vital for survival, as delays can cause fatal coagulopathy without prompt therapeutic intervention of all‐trans retinoic acid and arsenic trioxide. Although APL is diagnosed using microscopy, immunophenotyping, and FISH/PCR for PML‐RARA, morphological overlap with acute myeloid leukemia (AML) ‐M5 and AML‐M2 complicates identification. In resource‐limited settings, unavailability of real time ‐quantitiative PCR (RQ‐PCR) or delays in FISH/qualitative RT‐PCR results increase the risk of missed or late diagnosis with fatal outcomes. Podoplanin (PDPN), a glycoprotein overexpressed in APL cells, interacts with platelets to mediate thrombosis. We evaluated PDPN expression, regulation, and diagnostic potential in APL. PDPN mRNA (RQ‐PCR) and surface protein (flow cytometry) were significantly higher in APL than non‐APL AML ( p < 0.0001), consistent with TCGA‐LAML and BEATAML1.0 datasets. Sensitivity and specificity were 80.7% and 71.43% by RQ‐PCR, and 92.86% and 100% by flow cytometry, respectively. Chromatin immunoprecipitation followed by quantitative PCR (ChIP‐qPCR) and TGF‐ β1 stimulation confirmed SMAD binding and PDPN upregulation. Pharmacological inhibition of TGF‐β1 ligand using luspatercept reduced SMAD phosphorylation and PDPN expression, indicating TGF‐β/SMAD transcriptionally regulates PDPN. Additionally, ELISA‐based serum profiling showed significantly elevated TGF‐β1 levels in APL patients compared to non‐APL AML ( p < 0.0001). These findings identify PDPN overexpression as a downstream consequence of TGF‐β/SMAD signaling and highlight its potential as a diagnostic biomarker for APL.

29 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
BMBernadette Mathew
Bernadette Mathew
AMAkash Maity
Akash Maity
RGRitwik Ganguly
Ritwik Ganguly
AHAbhishek Halder
Abhishek Halder
JSJustin Thomas Sabu
Justin Thomas Sabu
Debarka SenguptaDebarka Sengupta
Debarka Sengupta
Connecting cell identity to biological function is central to understanding how tumors change during treatment. Here, we introduce scKNIFE, a knowledge-guided nonnegative matrix factorization framework that integrates gene expression with a heterogeneous graph of functional annotations, metabolic reactions and metabolites, and signaling interactions. scKNIFE jointly learns cellular representations and biological-entity loadings, linking the factors that organize cells to their constituent genes and connected functions. Across breast-cancer cohorts, the learned representations retained broad cellular organization without using per-cell identity labels as factorization targets. scKNIFE identified baseline tumor programs associated with subsequent clinical response or T-cell clonotype expansion and resolved treatment-associated functional variation within immune and stromal populations. In a seven-patient triple-negative breast cancer atlas, analysis alongside tissue metabolomics identified distinct trajectories of inferred fatty acid activation and carnitine-associated activities, including higher myeloid L-octanoylcarnitine scores at biopsy in all seven patients. Communication analysis further resolved an endothelial-perivascular PDGF connection with lower inferred scores at surgery in six patients. scKNIFE brings cellular identity, metabolic programs and candidate intercellular communication into one representation, enabling functional interpretation of tumor heterogeneity across patients and treatment states.